117 related articles for article (PubMed ID: 21960357)
1. Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.
McCawley N; Conlon S; Hector S; Cummins RJ; Dicker P; Johnston PG; Kay EW; McNamara DA; Prehn JH; Concannon CG
Int J Cancer; 2012 Aug; 131(4):E494-500. PubMed ID: 21960357
[TBL] [Abstract][Full Text] [Related]
2. Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer.
Boland K; Flanagan L; McCawley N; Pabari R; Kay EW; McNamara DA; Murray F; Byrne AT; Ramtoola Z; Concannon CG; Prehn JH
Eur J Pharmacol; 2016 Jun; 780():53-64. PubMed ID: 26997367
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
5. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Role of STEAP1 Expression Determined via Immunohistochemistry Staining in Predicting Prognosis of Primary Colorectal Cancer: A Survival Analysis.
Lee CH; Chen SL; Sung WW; Lai HW; Hsieh MJ; Yen HH; Su TC; Chiou YH; Chen CY; Lin CY; Chen ML; Chen CJ
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104516
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.
Boye K; Jacob H; Frikstad KA; Nesland JM; Maelandsmo GM; Dahl O; Nesbakken A; Flatmark K
Cancer Med; 2016 Aug; 5(8):1840-9. PubMed ID: 27273130
[TBL] [Abstract][Full Text] [Related]
8. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers.
Krajewska M; Kim H; Kim C; Kang H; Welsh K; Matsuzawa S; Tsukamoto M; Thomas RG; Assa-Munt N; Piao Z; Suzuki K; Perucho M; Krajewski S; Reed JC
Clin Cancer Res; 2005 Aug; 11(15):5451-61. PubMed ID: 16061861
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
Williams DS; Mouradov D; Browne C; Palmieri M; Elliott MJ; Nightingale R; Fang CG; Li R; Mariadason JM; Faragher I; Jones IT; Churilov L; Tebbutt NC; Gibbs P; Sieber OM
Mod Pathol; 2020 Mar; 33(3):483-495. PubMed ID: 31471586
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
Huang Y; Yu H; Lei H; Xie C; Zhong Y
Med Oncol; 2014 Mar; 31(3):824. PubMed ID: 24469951
[TBL] [Abstract][Full Text] [Related]
11. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
Lin LW; Lai PS; Chen YY; Chen CY
Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer.
Koch M; Kienle P; Kastrati D; Antolovic D; Schmidt J; Herfarth C; von Knebel Doeberitz M; Weitz J
Int J Cancer; 2006 Jun; 118(12):3072-7. PubMed ID: 16425256
[TBL] [Abstract][Full Text] [Related]
13. ATAD2 overexpression is associated with progression and prognosis in colorectal cancer.
Hou M; Huang R; Song Y; Feng D; Jiang Y; Liu M
Jpn J Clin Oncol; 2016 Mar; 46(3):222-7. PubMed ID: 26819280
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
15. Laminin β3 expression as a prognostic factor and a predictive marker of chemoresistance in colorectal cancer.
Fukazawa S; Shinto E; Tsuda H; Ueno H; Shikina A; Kajiwara Y; Yamamoto J; Hase K
Jpn J Clin Oncol; 2015 Jun; 45(6):533-40. PubMed ID: 25770060
[TBL] [Abstract][Full Text] [Related]
16. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
[TBL] [Abstract][Full Text] [Related]
17. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.
Lin L; Piao J; Gao W; Piao Y; Jin G; Ma Y; Li J; Lin Z
BMC Cancer; 2013 Jul; 13():366. PubMed ID: 23902796
[TBL] [Abstract][Full Text] [Related]
18. γ-Catenin is an independent prognostic marker in early stage colorectal cancer.
Nagel JM; Kriegl L; Horst D; Engel J; Gautam S; Mantzoros CS; Kirchner T; Göke B; Kolligs FT
Int J Colorectal Dis; 2010 Nov; 25(11):1301-9. PubMed ID: 20737155
[TBL] [Abstract][Full Text] [Related]
19. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting prognosis in metastatic colorectal cancer patients.
Eker B; Ozaslan E; Karaca H; Berk V; Bozkurt O; Inanc M; Duran AO; Ozkan M
Asian Pac J Cancer Prev; 2015; 16(7):3015-21. PubMed ID: 25854399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
